Szeged

• A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in … Not authorised
  2022-500044-38-00 4 Chronic Kidney Disease associated Pruritus
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• Brain cancer and changes in immune system Pending
  2024-512136-30-00 6 Glioblastoma multiforme
• ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending
  2024-513824-41-00 6 Childhood non-mature-B Acute Lymphoblastic Leukemia
• Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria. Pending
  2024-518786-10-01 4 Moderate to Severe Chronic Spontaneous Urticaria
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Assessing the efficacy of Elixirium thymi compositum in the treatment of acute bronchitis in pediatric patients (EXOTIC): A double-blind, ra … Pending
  2025-520845-61-00 6 Acute bronchitis
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• ​A study to evaluate safety and explore efficacy of new lipase NHS7108 compared with pancrelipase in adult participants with exocrine pancre … Pending
  2025-521816-20-00 4 ​​Exocrine Pancreatic Insufficiency​
• Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, … Pending
  2025-521985-82-00 4 Diabetic sensorimotor polyneuropathy (DSPN)
• A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma … Pending
  2025-522076-85-00 4 Rheumatoid arthritis
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Pending
  2025-522511-42-00 4 Crohn's disease
• A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w … Pending
  2025-522542-40-00 5 Acute Ischemic Stroke
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy … Pending
  2025-523010-89-00 3 Pulmonary arterial hypertension
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5 Obesity
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis

Showing 1–24 of 320 trials